Piper Jaffray analyst William Quirk notes that a German contractor assessing breast cancer biomarker tests recently released its report finding there was "no hint of a benefit or harm" using Myriad Genetics' (MYGN) EndoPredict and Agendia's MammaPrint. Genomic Health's (GHDX) Oncotype DX Breast was not extensively reviewed since there were no relevant studies with long-term outcomes, the analyst points out. Should the German Federal Ministry of Health, which makes the final determination on reimbursement, follow the report's recommendation, there will likely be no breast cancer test gaining reimbursement, Quirk tells investors in a research note. He believes such a move would be an incremental negative for Genomic Health and Myriad.